ES2032194T3 - Solubilizacion de agregados proteicos. - Google Patents

Solubilizacion de agregados proteicos.

Info

Publication number
ES2032194T3
ES2032194T3 ES198686309603T ES86309603T ES2032194T3 ES 2032194 T3 ES2032194 T3 ES 2032194T3 ES 198686309603 T ES198686309603 T ES 198686309603T ES 86309603 T ES86309603 T ES 86309603T ES 2032194 T3 ES2032194 T3 ES 2032194T3
Authority
ES
Spain
Prior art keywords
solubilization
protein
imperficiative
agent
source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686309603T
Other languages
English (en)
Spanish (es)
Inventor
Joseph John Patroni
Malcolm Roy Brandon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FIDELITY FOOD TECHNOLOGIES PTY Ltd
Original Assignee
FIDELITY FOOD TECHNOLOGIES PTY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FIDELITY FOOD TECHNOLOGIES PTY Ltd filed Critical FIDELITY FOOD TECHNOLOGIES PTY Ltd
Application granted granted Critical
Publication of ES2032194T3 publication Critical patent/ES2032194T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES198686309603T 1985-12-11 1986-12-10 Solubilizacion de agregados proteicos. Expired - Lifetime ES2032194T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPH381885 1985-12-11

Publications (1)

Publication Number Publication Date
ES2032194T3 true ES2032194T3 (es) 1993-01-16

Family

ID=3771404

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198686309603T Expired - Lifetime ES2032194T3 (es) 1985-12-11 1986-12-10 Solubilizacion de agregados proteicos.

Country Status (14)

Country Link
US (1) US4797474A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0226448B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0660198B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN86108729A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE76878T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU597924B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1281849C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3685562T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK171331B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2032194T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3004903T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY101204A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO864990L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ218586A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
AU612133B2 (en) * 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) * 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5654176A (en) * 1987-05-28 1997-08-05 Amrad Corporation Limited Fusion proteins containing glutathione-s-transferase
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
EP0295859B1 (en) * 1987-06-15 1994-11-17 Southern Cross Biotech Pty.Ltd. Production of proteins in active forms
US5266205A (en) * 1988-02-04 1993-11-30 Battelle Memorial Institute Supercritical fluid reverse micelle separation
US5637566A (en) * 1988-08-24 1997-06-10 Southern Cross Biotech Pty. Ltd. Method of improving carcass quality by administering growth hormone
US5136027A (en) * 1989-05-02 1992-08-04 Abbott Laboratories Method for renaturing proteins in the presence of alkyl sulfate detergents
DE69122280T2 (de) * 1990-03-01 1997-04-24 Hewlett Packard Co Minimierung von Eluatbandbreiten in der Flüssigchromatographie
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins
DE69222384T2 (de) * 1991-08-26 1998-04-02 Hewlett Packard Co Palo Alto Chromatographisches Verfahren mit micellarer Anreicherung in der Säule
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
WO1998002151A2 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
CN1896231B (zh) 1998-08-06 2012-09-05 山景药品公司 分离四聚体尿酸氧化酶的方法
AU2003298594A1 (en) * 2002-11-01 2004-06-07 Promega Corporation Cell lysis compositions, methods of use, apparatus, and kit
DE10309691B4 (de) 2003-02-28 2018-10-04 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Gewinnung von löslichen Proteinen aus der Biomasse rekombinanter Mikroorganismen
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CA2604399A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
CN101194016B (zh) 2005-04-11 2012-09-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
WO2007069673A1 (ja) * 2005-12-14 2007-06-21 Denka Seiken Co., Ltd. 多剤耐性ブドウ球菌のイムノクロマトグラフィー検出法および診断キット
ES2532804T3 (es) * 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
US8663725B2 (en) * 2007-10-05 2014-03-04 Advance International Inc. Method for deriving a high-protein powder/ omega 3 oil and double distilled water from any kind of fish or animal ( protein)
US9706787B2 (en) * 2007-10-05 2017-07-18 Advance International Inc. Systems and methods for deriving protein powder
SG10201408480RA (en) 2009-06-25 2015-02-27 Crealta Pharmaceuticals Llc Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy
JP2015519361A (ja) 2012-05-31 2015-07-09 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 正電荷有機添加剤での処理によるタンパク質製剤におけるタンパク質−不純物複合体及び凝集体のレベルを低下させるための方法
US9826757B2 (en) 2013-03-15 2017-11-28 Advance International Inc. Automated method and system for recovering protein powder meal, pure omega 3 oil and purified distilled water from animal tissue
WO2014192877A1 (ja) * 2013-05-29 2014-12-04 Jsr株式会社 洗浄用組成物、タンパク質精製方法、及びタンパク質
WO2015130223A1 (en) 2014-02-27 2015-09-03 Agency For Science, Technology And Research Methods for reducing chromatin content in protein preparations by treatment with alkyl cations
CA2920789C (en) 2015-06-04 2021-05-18 Advance International, Inc. Improved methods and systems for recovering protein powder and natural omega-3 oil from animal tissue
WO2019103106A1 (ja) * 2017-11-22 2019-05-31 学校法人東京薬科大学 凝集タンパク質の再生剤およびこれを用いた凝集タンパク質の再生方法
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2829089A1 (de) * 1977-07-13 1979-02-01 Sandoz Ag Subunit-vakzine
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4659568A (en) * 1985-02-27 1987-04-21 American Cyanamid Company Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom
US4656255A (en) * 1985-09-09 1987-04-07 International Minerals & Chemical Corp. Protein recovery
WO1988000942A2 (en) * 1986-07-28 1988-02-11 Allied Corporation Sulfonate benzotriazoles and their use in polyamide

Also Published As

Publication number Publication date
US4797474A (en) 1989-01-10
GR3004903T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-04-28
DK592186A (da) 1987-06-12
DE3685562D1 (de) 1992-07-09
NO864990L (no) 1987-06-12
DK171331B1 (da) 1996-09-09
CA1281849C (en) 1991-03-19
DK592186D0 (da) 1986-12-10
ATE76878T1 (de) 1992-06-15
DE3685562T2 (de) 1992-12-24
EP0226448A2 (en) 1987-06-24
MY101204A (en) 1991-08-17
JPH0660198B2 (ja) 1994-08-10
NO864990D0 (no) 1986-12-10
NZ218586A (en) 1989-07-27
AU597924B2 (en) 1990-06-14
EP0226448A3 (en) 1989-01-11
AU6687486A (en) 1987-06-18
EP0226448B1 (en) 1992-06-03
JPS62223192A (ja) 1987-10-01
CN86108729A (zh) 1987-10-21

Similar Documents

Publication Publication Date Title
ES2032194T3 (es) Solubilizacion de agregados proteicos.
ES2065911T3 (es) Produccion de proteinas en formas activas.
DE3484616D1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
ATE292473T1 (de) Thymosin beta 4 stimuliert wundheilung
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
ES2136599T3 (es) Tratamiento de las heridas utilizando peptidos biologicamente activos.
ATE120091T1 (de) Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz.
CA2005016A1 (en) Dna fragment containing promoter region for human polypeptide chain elongation factor-1.alpha. and expression plasmid containing the dna fragment
ES2056817T3 (es) Transformacion de trichoderma.
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
SE8602405L (sv) Ny formulering
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ATE125268T1 (de) Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein- komplexes.
AR034226A2 (es) Procedimiento perfeccionado para estabilizar proteinas.
NZ335385A (en) Active hedgehog conjugate, process for its production and use
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
TR199802648A2 (xx) Gen tedavisi i�in n�klein asit yap�lar�.
IT1232318B (it) Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
ES2011016B3 (es) Composicion detergente liquida.
ATE70453T1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
EP0315118A3 (en) Dna coding for endothelin and use thereof
BR0102085A (pt) Material de eletrodo-positivo reduzido em célulaseletroquìmicas, processo para sua preparação,seu uso, célula eletroquìmica, bem como uso deóxido de estanho reduzido
ES2000435T3 (es) Procedimiento de purificacion de antigenos proteinicos de bacterias que pertenecen al genero bordetella, en vista a la obtencion de una vacuna acelular.
ES2056149T3 (es) Ambliommina, una nueva sustancia activa para la terapia anticoagulante.